What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Surgery
Internal medicine, Surgery, Oncology, Melanoma and Cancer are her primary areas of study.
Katherine S. Panageas combines subjects such as Gastroenterology and Pathology with her study of Internal medicine.
She interconnects Clinical trial and Epidemiology in the investigation of issues within Surgery.
The Oncology study combines topics in areas such as Tolerability, Cumulative incidence, Retrospective cohort study and Lung.
Her studies deal with areas such as Immune system, Immunology, Ipilimumab and Family history as well as Melanoma.
Her Cancer study combines topics from a wide range of disciplines, such as Disease, Soft tissue, Myocardial infarction, Thrombosis and Median survival.
Her most cited work include:
- How To Build and Interpret a Nomogram for Cancer Prognosis (864 citations)
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response (670 citations)
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center (557 citations)
What are the main themes of her work throughout her whole career to date?
Katherine S. Panageas focuses on Internal medicine, Oncology, Melanoma, Surgery and Cancer.
Her work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Pathology.
Her biological study spans a wide range of topics, including Proportional hazards model, Disease, Retrospective cohort study and Phases of clinical research.
Katherine S. Panageas has included themes like Immunology, Immune system and Immunotherapy in her Melanoma study.
Her Immune system research is multidisciplinary, relying on both Cytotoxic T cell, Antibody and Antigen.
Her Cancer research is multidisciplinary, incorporating perspectives in Epidemiology and Cohort.
She most often published in these fields:
- Internal medicine (53.73%)
- Oncology (36.47%)
- Melanoma (27.84%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (53.73%)
- Oncology (36.47%)
- Melanoma (27.84%)
In recent papers she was focusing on the following fields of study:
Her primary scientific interests are in Internal medicine, Oncology, Melanoma, Cancer and Cancer research.
Her Internal medicine study typically links adjacent topics like Gastroenterology.
Her work in the fields of Oncology, such as Progression-free survival, overlaps with other areas such as Perifosine.
Her Melanoma study combines topics in areas such as Nivolumab, Ipilimumab, Immunotherapy and Long term outcomes.
Katherine S. Panageas has researched Cancer in several fields, including Odds ratio, Epidemiology and Emergency medicine.
Her Cancer research research is multidisciplinary, incorporating elements of Immune checkpoint, T cell, CD8, Immune system and Kinase.
Between 2018 and 2021, her most popular works were:
- Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid (136 citations)
- Arterial thromboembolic events preceding the diagnosis of cancer in older persons. (59 citations)
- Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. (59 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Her primary areas of investigation include Internal medicine, Oncology, Melanoma, In patient and Clinical trial.
Her study connects Gastroenterology and Internal medicine.
Her research in Oncology intersects with topics in Glioblastoma, Neurology, Chemotherapy and EGFR Amplification.
Her Melanoma research includes elements of Stage, Nivolumab, Ipilimumab and Cohort.
Her study in Clinical trial is interdisciplinary in nature, drawing from both Methotrexate, Ibrutinib, Refractory and Rituximab.
Her Cancer research incorporates elements of Odds ratio, Absolute risk reduction, Epidemiology, Myocardial infarction and Diagnosis code.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
